ATE314396T1 - G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung - Google Patents

G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung

Info

Publication number
ATE314396T1
ATE314396T1 AT99918932T AT99918932T ATE314396T1 AT E314396 T1 ATE314396 T1 AT E314396T1 AT 99918932 T AT99918932 T AT 99918932T AT 99918932 T AT99918932 T AT 99918932T AT E314396 T1 ATE314396 T1 AT E314396T1
Authority
AT
Austria
Prior art keywords
screening
csf receptor
receptor agonist
agonist antibodies
receptor
Prior art date
Application number
AT99918932T
Other languages
English (en)
Inventor
Baofu Ni
Bill N C Sun
Cecily R Y Sun
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Application granted granted Critical
Publication of ATE314396T1 publication Critical patent/ATE314396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99918932T 1998-04-30 1999-04-30 G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung ATE314396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8357598P 1998-04-30 1998-04-30
PCT/US1999/009466 WO1999055735A1 (en) 1998-04-30 1999-04-30 G-csf receptor agonist antibodies and screening method therefor

Publications (1)

Publication Number Publication Date
ATE314396T1 true ATE314396T1 (de) 2006-01-15

Family

ID=22179233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918932T ATE314396T1 (de) 1998-04-30 1999-04-30 G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung

Country Status (12)

Country Link
EP (1) EP1073683B1 (de)
JP (1) JP3979008B2 (de)
KR (1) KR100479790B1 (de)
CN (2) CN1326880C (de)
AT (1) ATE314396T1 (de)
AU (2) AU764653B2 (de)
BR (1) BR9910568A (de)
CA (1) CA2326755A1 (de)
DE (1) DE69929183T2 (de)
ES (1) ES2253887T3 (de)
NZ (1) NZ507782A (de)
WO (1) WO1999055735A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240197A1 (en) * 2001-02-01 2002-08-12 Tanox, Inc. Methods to generate and identify monoclonal antibodies to a large number of human antigens
CN103272232B (zh) 2006-06-08 2018-07-24 中外制药株式会社 炎性疾病的预防或治疗药
JP5174019B2 (ja) * 2007-06-07 2013-04-03 恵一 福田 Ｇ−ｃｓｆを用いた心筋細胞への分化誘導方法
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
JP6215056B2 (ja) 2011-03-01 2017-10-18 ノヴォ ノルディスク アー／エス 拮抗性ｄｒ３リガンド
KR102514173B1 (ko) 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
JP6782716B2 (ja) * 2015-06-25 2020-11-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体またはリガンドの結合および機能を明らかにするための細胞ベースアッセイ法
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation
CN117836326A (zh) * 2021-08-26 2024-04-05 协和麒麟株式会社 与cd116和cd131结合的双特异性抗体
CN114292843B (zh) * 2021-12-03 2023-07-21 中国科学院精密测量科学与技术创新研究院 一种基因兴奋剂的CRISPR/Cas12a检测体系及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
AUPM375094A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
AU717733B2 (en) * 1995-10-05 2000-03-30 G.D. Searle & Co. Novel G-CSF receptor agonists

Also Published As

Publication number Publication date
AU3673299A (en) 1999-11-16
AU764653B2 (en) 2003-08-28
NZ507782A (en) 2003-12-19
CN1326880C (zh) 2007-07-18
KR20010043112A (ko) 2001-05-25
WO1999055735A1 (en) 1999-11-04
DE69929183D1 (de) 2006-02-02
DE69929183T2 (de) 2006-08-24
CN101070344A (zh) 2007-11-14
JP2002512782A (ja) 2002-05-08
BR9910568A (pt) 2001-09-11
AU2003252863A1 (en) 2003-11-06
EP1073683B1 (de) 2005-12-28
JP3979008B2 (ja) 2007-09-19
EP1073683A1 (de) 2001-02-07
CN1298412A (zh) 2001-06-06
CA2326755A1 (en) 1999-11-04
ES2253887T3 (es) 2006-06-01
EP1073683A4 (de) 2001-08-22
KR100479790B1 (ko) 2005-03-30

Similar Documents

Publication Publication Date Title
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
WO2005058815A3 (en) Ip-10 antibodies and their uses
ATE314396T1 (de) G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung
IL183160A0 (en) Indazole-carboxamide compounds
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
SG160224A1 (en) Novel peptides that bind to the erythropoietin receptor
CY1112101T1 (el) Νευροτροφικοι παραγοντες
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
MX2009002418A (es) Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2009067546A3 (en) Lung cancer markers and uses thereof
DE60028970D1 (de) An her2 bindende peptidverbindungen
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
NO20011759L (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
CA2395724A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
EP1433792A8 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
Benjamin et al. Platelet-derived growth factor stimulates growth factor receptor binding protein-2 association with Shc in vascular smooth muscle cells.
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
BR0308401A (pt) Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.
WO1999046379A3 (en) Human receptor proteins; related reagents and methods

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties